Side-by-side · Research reference

DermorphinvsIGF-DES

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BAnimal-StrongHUMAN-REVIEWED8/60 cited

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

01Mechanism of Action

Parameter

Dermorphin

IGF-DES

Primary target

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

IGF-1 receptor (IGF1R)Shields 2007

Pathway

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Downstream effect

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Feedback intact?

N/A — exogenous opioid agonist

Unknown — no human endocrine feedback data

Origin

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Antibody development

Site-directed antibodies produced for detection and purificationCucumel 1996

—

02Dosage Protocols

Parameter

Dermorphin

IGF-DES

Legal status

Controlled substance in many jurisdictions · Research only

Not approved for human use.

—

Animal research (ICV)

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

—

Detection limit (doping)

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

—

Duration of action

10–120 minutes (dose-dependent, intrathecal)

—

Evidence basis

Animal studies · In vitro assays

Animal models + in vitro only

Human toxicity

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

—

Research dose range

—

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

Route

—

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

Frequency

—

Variable — daily to multiple times daily in research

Human data

—

None — no clinical trials

Half-life

—

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

03Metabolic / Fat Loss Evidence

Parameter

Dermorphin

IGF-DES

Primary mechanism

—

Indirect via muscle hypertrophy → metabolic rate elevation

Direct lipolysis

—

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

Prostate model

—

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

04Side Effects & Safety

Parameter

Dermorphin

IGF-DES

Opioid effects

Respiratory depression, sedation, euphoria, tolerance, dependence risk

—

CNS effects

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

—

Kambô ritual toxicity

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

—

Peripheral effects

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

—

Receptor selectivity caveat

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

—

Proteolytic stability

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

—

Hypoglycemia risk

—

Theoretical — IGF-1 axis enhances glucose uptake

Mitogenic risk

—

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

Injection site reaction

—

Expected — erythema, irritation, local swelling

Edema / Fluid retention

—

Possible via sodium retention (IGF-1 axis effect)

Human safety data

—

Absent — no human trials, all effects theoretical or extrapolated

Unknown long-term effects

—

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

Absolute Contraindications

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Relative Contraindications

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

05Administration Protocol

Parameter

Dermorphin

IGF-DES

1. Legal and ethical framework

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

2. Animal research protocols

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

3. Analytical detection

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

4. Kambô ritual (traditional use)

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

5. Needle gauge

—

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

6. Monitoring

—

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

06Stack Synergy

Dermorphin

— no documented stacks

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support